Unleash Immuno Oncolytics

Unleash Immuno Oncolytics is a privately held biotechnology company headquartered in St. Louis, Missouri. The company employs 6 individuals and generates approximately $2.5 million in annual revenue. Unleash IO specializes in developing oncolytic immunotherapy products, focusing primarily on UIO-512, an oncolytic adenovirus. This innovative therapy targets both malignant cells and tumor-associated stroma cells, utilizing GM-CSF, a potent immune-modulatory cytokine, to trigger an immune response against tumors. UIO-512's primary indication is ovarian cancer, with further applications explored in glioblastoma, melanoma, and pancreatic cancer. Unleash IO's commitment to scientific rigor is evident in the publication of promising pre-clinical results in top-ranked peer-reviewed journals, showcasing the efficacy of UIO-512 in animal models and human samples of ovarian cancer and melanoma. Interested parties can visit Unleash IO's website at www.unleash.bio for more information.